Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

NanoString Technologies Appoints Senior Financial Executive

Published: Wednesday, July 18, 2012
Last Updated: Wednesday, July 18, 2012
Bookmark and Share
Greg Norden welcomed to Board of Directors. Mr. Norden will serve as the Chairman of NanoString's Audit Committee.

Mr. Norden is a senior executive with more than 25 years of leadership in financial management and strategy, including a 21-year career at Wyeth, where he was most recently Senior Vice President and Chief Financial Officer. Wyeth was acquired by Pfizer in October 2009 in a transaction valued at $68 billion. Prior to his corporate CFO role, Mr. Norden was Executive Vice President and Chief Financial Officer, Wyeth Pharmaceuticals and held a number of other positions of increasing responsibility from initially joining Wyeth/American Home Products in 1989. Earlier in his career, Mr. Norden worked at Arthur Andersen & Co.

"With a rapidly growing life sciences business and a capability for developing high-value molecular diagnostics, NanoString Technologies is poised to transform both the study and treatment of disease," said Mr. Norden. "I am excited to join NanoString's Board of Directors, and to help the company scale these businesses."

Mr. Norden received his B.S. from the State University of New York - Plattsburgh and received his M.S. from Long Island University - C. W. Post. He also serves on the Board of Directors of Human Genome Sciences /quotes/zigman/55662/quotes/nls/hgsi HGSI +0.04% , a public biopharmaceutical company, and WelchAllyn, a leading global provider of medical diagnostic equipment.

"Greg brings more than two decades of healthcare industry experience and an impeccable track record of leading financial and administrative operations," said William D. Young, Executive Chairman of the Board for NanoString Technologies. "We look forward to benefiting from his experience as CFO of a global Fortune 120 corporation as we prepare for the next stage of NanoString's growth."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NanoString, Medivation, Astellas Collaborate
NanoString eligible to receive up to $22 million for technology access, near-term milestones and development funding.
Friday, January 08, 2016
NanoString Technologies Receives FDA 510(k) Clearance for Prosigna™ Breast Cancer Prognostic Gene Signature Assay
Prosigna assay on the nCounter® Dx analysis system provides compelling clinical data, clear patient report, and decentralized testing in qualified labs.
Tuesday, September 17, 2013
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Clamping Down on Biomolecules
Physicists have developed a novel nanotool that provides a means of characterizing the mechanical properties of biomolecules.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos